Angela Hwang is a member of Pfizer’s Executive Team and Group President of the Pfizer Biopharmaceuticals Group, which comprises the entire commercial organization of Pfizer. Her organization of 26,000 colleagues across 125 countries is responsible for bringing over 600 innovative medicines and products to patients. In 2019, Pfizer Biopharma generated around $40 billion in revenues. As Group President, Angela leads 7 commercial business units delivering medicines that address major global health priorities in cancer, rare disease, inflammation & immunology, primary care, infectious diseases, and preventative care with vaccines. In 2020, over 420 million people benefited from a Pfizer Biopharma medicine or vaccine. Angela has been with Pfizer for 23 years, working across all geographies and therapeutic areas. She is motivated by the common purpose that all Pfizer colleagues share, to bring breakthroughs to patients, regardless of where they are in the world.
She is a member of the Board of Directors of UPS, EFPIA, and the Pfizer Foundation, a charitable organization. In 2019, she was named in Crain’s Notable Women in Healthcare list, and in 2020 she was ranked #16 in Fortune’s Top 50 Most Powerful Women. Angela received her Bachelor of Science in Microbiology and Biochemistry from the University of Cape Town and MBA from Cornell University.